drugset / Trial / NCT03524846

Ascorbic Acid on Restenosis of Dysfunctional Hemodialysis Vascular Access

NCT03524846

RandomizedParallel-groupOpen-labelTreatment

Summary

To investigate the effect of ascorbic acid on angiographic restenosis after percutaneous transluminal angioplasty (PTA) for dysfunctional dialysis vascular access.

Timeline

Start
2011-04
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Vitamin C Other / unclassified 300 mg Intravenous
Comparator Vitamin C Other / unclassified 600 mg Intravenous

Indications

No indication recorded.